Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Coherus Oncology (CHRS) Receivables - Other (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Receivables - Other for 5 consecutive years, with $603000.0 as the latest value for Q4 2025.

  • Quarterly Receivables - Other fell 94.52% to $603000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $603000.0 through Dec 2025, down 94.52% year-over-year, with the annual reading at $603000.0 for FY2025, 94.52% down from the prior year.
  • Receivables - Other hit $603000.0 in Q4 2025 for Coherus Oncology, down from $241.3 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $241.3 million in Q3 2025 to a low of $603000.0 in Q4 2025.